JP2013514372A - 虚血および虚血−再灌流傷害におけるマイクロｒｎａ調節 - Google Patents

虚血および虚血−再灌流傷害におけるマイクロｒｎａ調節 Download PDF

Info

Publication number
JP2013514372A
JP2013514372A JP2012544748A JP2012544748A JP2013514372A JP 2013514372 A JP2013514372 A JP 2013514372A JP 2012544748 A JP2012544748 A JP 2012544748A JP 2012544748 A JP2012544748 A JP 2012544748A JP 2013514372 A JP2013514372 A JP 2013514372A
Authority
JP
Japan
Prior art keywords
mir
mirna
subject
mirnas
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012544748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514372A5 (cg-RX-API-DMAC7.html
Inventor
エヌ． オルソン，エリック
ヴァン ルーイジ，エヴァ
キアット，ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2013514372A publication Critical patent/JP2013514372A/ja
Publication of JP2013514372A5 publication Critical patent/JP2013514372A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012544748A 2009-12-15 2010-12-15 虚血および虚血−再灌流傷害におけるマイクロｒｎａ調節 Pending JP2013514372A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28662209P 2009-12-15 2009-12-15
US61/286,622 2009-12-15
PCT/US2010/060460 WO2011084460A1 (en) 2009-12-15 2010-12-15 Micro-rna regulation in ischemia and ischemia-reperfusion injury

Publications (2)

Publication Number Publication Date
JP2013514372A true JP2013514372A (ja) 2013-04-25
JP2013514372A5 JP2013514372A5 (cg-RX-API-DMAC7.html) 2014-02-06

Family

ID=44305697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012544748A Pending JP2013514372A (ja) 2009-12-15 2010-12-15 虚血および虚血−再灌流傷害におけるマイクロｒｎａ調節

Country Status (8)

Country Link
US (1) US20130005658A1 (cg-RX-API-DMAC7.html)
EP (1) EP2513307A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013514372A (cg-RX-API-DMAC7.html)
CN (1) CN102791859A (cg-RX-API-DMAC7.html)
AU (1) AU2010340062A1 (cg-RX-API-DMAC7.html)
CA (1) CA2784118A1 (cg-RX-API-DMAC7.html)
RU (1) RU2012129900A (cg-RX-API-DMAC7.html)
WO (1) WO2011084460A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150135657A (ko) * 2014-05-23 2015-12-03 강원대학교산학협력단 혈관신생을 촉진하는 마이크로rna-101

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
EP2683411B1 (en) * 2011-03-09 2016-01-13 The Brigham and Women's Hospital, Inc. Methods of using microrna-26a to promote angiogenesis
US8871731B2 (en) 2011-03-16 2014-10-28 Migagen Therapeutics, Inc. Micro-RNA for the regulation of cardiac apoptosis and contractile function
SG194901A1 (en) * 2011-05-09 2013-12-30 Univ Glasgow Methods of modulating micrornas in the treatment of pulmonary arterial hypertension
EP2584040A1 (en) 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Compounds for treatment of ischemic injury
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN102965429B (zh) * 2012-03-15 2015-03-04 汪道文 microRNA-320(miR-320a)及其反义核苷酸在诊断、防治心血管疾病中的用途
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US9845465B2 (en) 2012-08-15 2017-12-19 University Of Virginia Patent Foundation Compositions and methods for treating peripheral arterial disease
US20160076026A1 (en) * 2013-03-15 2016-03-17 The Hospital For Sick Children Diagnostic and therapeutic methods relating to microrna-144
EP3200808B1 (en) 2014-10-03 2024-07-31 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2016113702A1 (en) * 2015-01-16 2016-07-21 Bioup Sagl Isolated genetically modified cell population
CN105251014B (zh) * 2015-08-17 2018-10-19 南昌大学 Nonratt021972小干扰rna在制备心肌缺血损伤、交感神经疾病药物中的应用
US10119139B2 (en) 2015-09-14 2018-11-06 Vanderbilt University Treatment for conditions associated with fibrosis and collagen deposition
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CN105695612A (zh) * 2016-04-19 2016-06-22 中南大学 microRNA-126-5p在心肌损伤中的表达检测方法
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
CN106692175A (zh) * 2016-12-26 2017-05-24 大连医科大学附属第二医院 miR‑665‑3p抑制物在制备防治缺血再灌注损伤药物中的应用
CN108245687A (zh) * 2016-12-29 2018-07-06 贾中芝 一种IpostC在抗肠再灌注损伤中所起作用的实验方法
WO2018183594A1 (en) * 2017-03-29 2018-10-04 Children's Hospital Medical Center Nucleic acid molecules and their methods of use
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MANIPULATED EXTRACELLULAR VESICLES FOR ENHANCED RELEASE INTO TISSUE
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
US11591597B2 (en) * 2018-04-20 2023-02-28 Texas Tech University System MicroRNAs as therapeutic targets for ischemic stroke
CN110205374A (zh) * 2019-06-17 2019-09-06 昆山德诺瑞尔生物科技有限公司 检测血小板中miR-34a基因表达量的引物、试剂盒、检测方法及其应用
CN110257508A (zh) * 2019-07-12 2019-09-20 宁夏医科大学 一种在衰老心肌缺血后处理缺血再灌注损伤治疗用miRNA标志物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008275877B2 (en) * 2007-07-18 2015-01-22 The Regents Of The University Of Colorado, A Body Corporate Differential expression of microRNAs in nonfailing versus failing human hearts
EP2182969B1 (en) * 2007-07-31 2016-11-16 The Board of Regents of The University of Texas System A micro-rna family that modulates fibrosis and uses thereof
WO2009114681A2 (en) * 2008-03-13 2009-09-17 Dharmacon, Inc. Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JPN6014050635; Ｃｉｒｃｕｌａｔｉｏｎ，　Ｖｏｌ．１１９　ｐ．２３５７-２３６６　（２００９　Ｍａｙ） *
JPN6014050639; Ｐｈｙｓｉｏｌ　Ｇｅｎｏｍｉｃｓ．，　Ｖｏｌ．３１　ｐ．３６７-３７３　（２００７） *
JPN6014050642; Ｐｈａｒｍａｃｏｌ　Ｔｈｅｒ．，　Ｖｏｌ．１２５　Ｎｏ．１　ｐ．９２-１０４　（Ｅｐｕｂ　２００９　Ｎｏｖ　６） *
JPN6014050646; Ｓｃｉｅｎｃｅ，　Ｖｏｌ．３２４　Ｎｏ．５９３５　ｐ．１７１０-１７１３　（２００９．０６．２６） *
JPN6014050649; Ｊ　Ｂｉｏｌ　Ｃｈｅｍ．，　Ｖｏｌ．２８４　Ｎｏ．４８　ｐ．３３１６１-３３１６８　（２００９．１１．２７） *
JPN6014050652; Ｂｉｏｃｈｅｍ　Ｂｉｏｐｈｙｓ　Ｒｅｓ　Ｃｏｍｍｕｎ．，　Ｖｏｌ．３８１　Ｎｏ．４　ｐ．５９７-６０１　（２００９．０４．１７） *
JPN6014050656; Ｊ　Ｂｉｏｌ　Ｃｈｅｍ．，　Ｖｏｌ．２８４　Ｎｏ．４３　ｐ．２９５１４-２９５２５　（２００９．１０．２３） *
JPN6014050659; ＩＵＢＭＢ　Ｌｉｆｅ，　Ｖｏｌ．６１　Ｎｏ．６　ｐ．５６６-５７１　（２００９．０６） *
JPN6014050661; ＦＥＢＳ　Ｌｅｔｔ．，　Ｖｏｌ．５８２　Ｎｏ．１６　ｐ．２３９７-２４０１　（２００８） *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150135657A (ko) * 2014-05-23 2015-12-03 강원대학교산학협력단 혈관신생을 촉진하는 마이크로rna-101
KR101668518B1 (ko) 2014-05-23 2016-10-24 강원대학교산학협력단 혈관신생을 촉진하는 마이크로rna-101

Also Published As

Publication number Publication date
WO2011084460A1 (en) 2011-07-14
US20130005658A1 (en) 2013-01-03
EP2513307A1 (en) 2012-10-24
CN102791859A (zh) 2012-11-21
EP2513307A4 (en) 2014-02-26
CA2784118A1 (en) 2011-07-14
AU2010340062A1 (en) 2012-07-12
RU2012129900A (ru) 2014-01-27

Similar Documents

Publication Publication Date Title
JP2013514372A (ja) 虚血および虚血−再灌流傷害におけるマイクロｒｎａ調節
CN102803284B (zh) 用于miRNA抑制剂和模拟物的化学修饰基序
US10337005B2 (en) Oligonucleotide-based inhibitors comprising locked nucleic acid motif
JP2012527478A (ja) 心筋梗塞後のリモデリングおよび心不全に関与するマイクロｒｎａの同定
US9163235B2 (en) Inhibitors of the miR-15 family of micro-RNAs
KR20100099158A (ko) 심근세포 생존과 심장 회복을 제어하는 ＭＩＲ-15 집단의 마이크로ＲＮＡｓ
WO2010120969A1 (en) Targeting of the mir-30 family and let-7 family as a treatment for heart disease
WO2014151835A1 (en) Locked nucleic acid inhibitor of mir-145 and uses thereof
HK1259394A1 (en) Oligonucleotide-based inhibitors comprising locked nucleic acid motif
Bonauer Die Bedeutung von microRNAs für die Funktion von Endothelzellen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150527